Skip to contentB
BioMarin Pharmaceutical Inc
B
BMRNBioMarin Pharmaceutical Inc Q3 2018 · 10-Q
Revenue$391.71M$391.71M+17.2% vs Q3 2017 Net Income-$12.62M-$12.62MN/M vs Q3 2017 EPS Diluted-$0.07-$0.07N/M vs Q3 2017 Operating Income-$15,741,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
BioMarin Pharmaceutical Inc · CIK 1048477 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$2,659,000N/M Margins · derivedOperating margin-4.0%+0.1 pt vs Q3 2017
Net margin-3.2%+0.5 pt vs Q3 2017
ended Sep 30, 2018 · filed Oct 26, 2018 · 26 d after period end